ArticleScientific reports2025

Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K/AKT signaling pathway.

Jiazhen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.